Latest news with #Scientist.com
Business Wire
23-07-2025
- Business
- Business Wire
Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models
SAN DIEGO--(BUSINESS WIRE)-- the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinically relevant tools. The addition of XenoSTART's models to Tumor Model Finder helps researchers find models with richer data and greater relevance to their specific cancer studies. 'Pharma discovery teams often face critical delays accessing translational research partners with deeply characterized PDX models that accurately reflect real-world patient disease complexity,' said Michael J. Wick, PhD, Chief Scientific Officer at XenoSTART. 'By joining the marketplace, XenoSTART eliminates this significant barrier, providing immediate access to our highly relevant, patient-derived tumor models that are directly linked to our global clinical network. This integration empowers drug developers to confidently accelerate therapeutic decision-making and precisely guide their translational strategies—ultimately speeding effective cancer treatments to patients.' Tumor Model Finder is a centralized, AI-powered platform that aggregates and standardizes tumor model data from 20+ leading CROs. It allows researchers to search, compare, and source PDX, CDX, organoid, and cell line models—spanning 17 cancer types—through a single workflow. The platform also includes drug response profiles, genomic alterations (e.g., KRAS, BRAF mutations), and RNA seq-based gene expression data to support informed model selection and study design. 'XenoSTART's contribution significantly boosts the depth and quality of our TMF offerings,' said Javier Pineda, PhD, Director of Preclinical AI at 'Researchers can now find models with richer data and greater relevance to their specific cancer studies.' This collaboration also highlights the translational impact of START's global research ecosystem. With patient-derived tissue samples sourced from START's expansive oncology trial network, XenoSTART's models provide critical continuity between preclinical evaluation and clinical trial execution—helping pharmaceutical companies make faster, more confident decisions in oncology drug development. To learn more or schedule a demo of the Tumor Model Finder, email diseasemodels@ About is the life-science industry's premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world's top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Visit to discover how we accelerate science. About XenoSTART Founded in 2007, XenoSTART is a translational research organization dedicated to advancing oncology drug development through clinically relevant preclinical cancer models. The XenoSTART Patient-Derived Xenograft (XPDX) platform features more than 2,800 models across a broad range of tumor types and disease stages sourced from patients treated at START's domestic and international cancer centers. Models are deeply characterized using histologic analysis, DNA/RNA sequencing, and in vivo drug sensitivity testing, and are clinically annotated with the donor patient's treatment history and clinical outcome. By bridging real-world tumor biology with rigorous preclinical science, XenoSTART enables pharmaceutical partners to make smarter, faster decisions from bench to bedside. Learn more about XenoSTART at
Business Wire
24-06-2025
- Business
- Business Wire
Promega Tailored R&D Solutions Available on Major Procurement Sites
MADISON, Wis.--(BUSINESS WIRE)--Promega Tailored R&D Solutions (TRS) is now listed on and Science Exchange, two of the largest platforms for connecting labs with Contract Research Organizations (CROs) and service providers. Promega TRS is a collaborative team that helps researchers and drug discovery clients to overcome capacity, expertise and technology gaps by developing custom solutions tailored to their specific needs. Researchers can engage with Promega TRS through these platforms to initiate custom assay development projects and screening services. "We're providing a streamlined, compliant way to engage with us through the systems they're already using.' Share 'These platforms simplify legal reviews, procurement workflows and invoicing, allowing researchers to focus more on the science and less on administrative tasks,' says Dave Lasky, Promega Director of Tailored R&D Solutions. 'By listing our TRS capabilities, we're providing a streamlined, compliant way to engage with us through the systems they're already using.' Promega TRS works with customers throughout the pharmaceutical and biotechnology industries, as well as government and academic institutions. Many of these organizations are already using and Science Exchange to connect with vendors. The new access to Promega TRS eliminates the need for separate contracts, NDAs or onboarding processes. Tailored R&D Solutions Promega TRS is a team that leverages innovative technologies and R&D expertise to build bespoke solutions for specific project goals. Unlike traditional CROs that follow rigid, task-based protocols, Promega TRS operates as a collaborative partner, applying Promega assay platforms to address complex questions through a flexible, milestone-driven workflow that adapts as new data emerge. Services offered by TRS include: Custom assay development: Target engagement, protein degradation, protein:protein interactions, Lumit® immunoassays Bioassays: potency assay optimization and qualification, thaw-and-use cell manufacturing Screening services: High-throughput screening (HTS), selectivity profiling, custom screening Custom materials: Vector design and synthesis, NanoBRET® Target Engagement tracers, Lumit® antibody/analyte labeling Each TRS project is supported by a dedicated project manager and involves direct access to the R&D teams involved in the development of key Promega technologies. Combining innovation, collaboration and operational excellence, the team helps labs accelerate decision making and reduce time to market. Learn more about Promega Tailored R&D Solutions here. About Promega Corporation Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at
Business Wire
05-06-2025
- Business
- Business Wire
Sarah Harkcom, General Counsel at Scientist.com, Wins European Legal Innovation & Technology 'Innovation Trailblazer' Award
SAN DIEGO--(BUSINESS WIRE)-- the leading R&D procurement-orchestration platform for the life sciences, today announced that its General Counsel, Sarah Harkcom, has been named Innovation Trailblazer at the 2025 European Legal Innovation & Technology Awards. legal framework has supported more than $2.5 billion in outsourced research, enabling scientists to launch critical experiments in days rather than weeks or months. Share Harkcom was recognized for architecting a unified, cross-border contracting model now adopted by many of the world's top pharmaceutical companies and contract research organizations (CROs). The framework has already supported more than $2.5 billion in outsourced research, enabling scientists to launch critical experiments in days rather than weeks or months. 'Sarah's vision reshaped how the pharma industry does business,' said Kevin Lustig, PhD, CEO and Founder of 'Her streamlined legal model removes friction for both buyers and suppliers, giving researchers faster access to the services they need to discover life-changing cures.' Key achievements Industry standardization: Created global template agreements that underlie most transactions. Accelerated R&D: Reduced contract-cycle times from months to days, a breakthrough that proved vital during the COVID-19 pandemic and continues to speed progress against other diseases. Global impact: The model's cross-jurisdictional design delivers uniform compliance and efficiency for partners in 80 countries. The awards ceremony took place on May 28 in Milan, Italy. For a full list of honorees, visit the European Legal Innovation & Technology Awards website. About makes it easy for life-science teams to find, vet and order the research services and products they need—often in days instead of weeks. Its online marketplace brings together 6,000+ pre-qualified suppliers across 1,000-plus research categories, all with built-in regulatory and data-privacy controls. The platform powers secure sourcing hubs for 20 of the world's top 30 pharmaceutical companies, 100+ biotech firms and the U.S. National Institutes of Health (NIH). Founded in 2007 and continually enhanced with AI tools, helps scientists spend less time on paperwork and more time on discovery. Learn more at
Yahoo
28-05-2025
- Business
- Yahoo
Scientist.com Adds Trial Insights™ to Clinical Labs Navigator™ Solution, Giving Researchers Instant Access to Global Clinical-Trial Intelligence
SAN DIEGO, May 28, 2025--(BUSINESS WIRE)-- the leading R&D procurement platform for the life sciences, today integrated Trial Insights™—its real‑time clinical‑trial analytics tool—into Clinical Labs Navigator™. The move lets scientists source lab services and query more than 500,000 active and completed trials from a single dashboard, shortening study‑planning cycles from weeks to hours. "Trial Insights turns scattered public and proprietary trial records into a live, searchable map," said Ron Ronauro, Founder of Trial Insights and VP of Applications at "A team can pull up any study, filter by endpoints, inclusion/exclusion criteria, enrollment progress or regulatory status, and instantly spot trends—without wrestling with spreadsheets." What's New Inside Clinical Labs Navigator Global trial coverage – Search 17 primary registries by phase, indication and geography. Biomarker explorer – See which markers drive response and how they trend across studies. Investigator & site profiles – Rank investigators by experience, therapeutic focus and startup speed. Drug & sponsor analytics – Track pipelines, competitors and partnership history in one view. Smart alerts – Get email or in‑app notifications when a trial you follow changes status, geography or enrollment targets. Availability Trial Insights is now live for all Clinical Labs Navigator users. New users can start a free trial or book a demo at For a live demo of Trial Insights and/or Clinical Labs Navigator, visit booth #15157 at the upcoming ASCO Annual Meeting in Chicago, IL. About makes it easy for life‑science teams to find, vet and order the research services and products they need—often in days instead of weeks. Its online marketplace brings together 6,000+ pre‑qualified suppliers across 1,000‑plus research categories, all with built‑in regulatory and data‑privacy controls. The platform powers secure sourcing hubs for 20 of the world's top 30 pharmaceutical companies, 100+ biotech firms and the U.S. National Institutes of Health (NIH). Founded in 2007 and continually enhanced with AI tools, helps scientists spend less time on paperwork and more time on discovery. Learn more at Clinical Labs Navigator and Trial Insights are trademarks of View source version on Contacts Preci+1 877-644-3044marketing@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
Scientist.com Adds Trial Insights™ to Clinical Labs Navigator™ Solution, Giving Researchers Instant Access to Global Clinical-Trial Intelligence
SAN DIEGO--(BUSINESS WIRE)-- the leading R&D procurement platform for the life sciences, today integrated Trial Insights™—its real‑time clinical‑trial analytics tool—into Clinical Labs Navigator™. The move lets scientists source lab services and query more than 500,000 active and completed trials from a single dashboard, shortening study‑planning cycles from weeks to hours. enhances Clinical Labs Navigator solution with addition of Trial Insights, providing researchers in the life sciences with real-time insights into global clinical-trial data. 'Trial Insights turns scattered public and proprietary trial records into a live, searchable map,' said Ron Ronauro, Founder of Trial Insights and VP of Applications at 'A team can pull up any study, filter by endpoints, inclusion/exclusion criteria, enrollment progress or regulatory status, and instantly spot trends—without wrestling with spreadsheets.' What's New Inside Clinical Labs Navigator Global trial coverage – Search 17 primary registries by phase, indication and geography. Biomarker explorer – See which markers drive response and how they trend across studies. Investigator & site profiles – Rank investigators by experience, therapeutic focus and startup speed. Drug & sponsor analytics – Track pipelines, competitors and partnership history in one view. Smart alerts – Get email or in‑app notifications when a trial you follow changes status, geography or enrollment targets. Availability Trial Insights is now live for all Clinical Labs Navigator users. New users can start a free trial or book a demo at For a live demo of Trial Insights and/or Clinical Labs Navigator, visit booth #15157 at the upcoming ASCO Annual Meeting in Chicago, IL. About makes it easy for life‑science teams to find, vet and order the research services and products they need—often in days instead of weeks. Its online marketplace brings together 6,000+ pre‑qualified suppliers across 1,000‑plus research categories, all with built‑in regulatory and data‑privacy controls. The platform powers secure sourcing hubs for 20 of the world's top 30 pharmaceutical companies, 100+ biotech firms and the U.S. National Institutes of Health (NIH). Founded in 2007 and continually enhanced with AI tools, helps scientists spend less time on paperwork and more time on discovery. Learn more at Clinical Labs Navigator and Trial Insights are trademarks of
